Tracking Measurements on Medisafe correlated with Improved Blood Pressure

24 Oct 2018

Study rationale

  • One in every three U.S. adults, about 78 million Americans, have high blood pressure, the single most important and most common risk factor for cardiovascular disease
  • Only 51% of Americans treated for hypertension are adherent to long-term medication therapy
  • Only 52% have their blood pressure under control
  • The total health and economic costs of all cardiovascular disease was more than $656 billion in 2015, with a projected cost of $1.2 trillion by 2030
  • The American Heart Association asserts that reducing average population systolic blood pressure by 12 to 13 mmHg could reduce incidence of stroke by 37%, coronary heart disease by 21%, and cardiovascular disease mortality by 25%

The NIH-funded SPRINT study published this year revealed that even more aggressive treatment targeting 120 mmHg systolic – as opposed to 140 mmHg – led to a 30% lower risk of adverse cardiovascular events and 25% lower risk of death.


Medisafe’s study examined 3 risk profiles:

1. Prehypertension (120 to 139 mmHg systolic)
2. Hypertension stage 1 (140 to 160 mmHg systolic)
3. Hypertension stage 2 (above 160 mmHg systolic)

To be included in the study and assigned to a risk profile, users needed at least two readings within a risk profile. These readings were then averaged to provide a baseline. The same logic and calculation was applied for the final week of readings. Medisafe limited the analysis to users reporting measurements via “connected devices” – WiFi- or Bluetooth-enabled blood pressure cuffs automatically transmitting levels to Medisafe to eliminate the potential for self-reporting bias.

Study results

  • With stage 1 hypertension (120-140 mmHg) decreased their systolic blood pressure by 17.7 mmHg
  • With stage 2 hypertension (over 160 mmHg) decreased their systolic blood pressure by 25.3 mmHg
  • With stage 1 or 2 hypertension reduced systolic blood pressure levels by an average of 19.3 mmHg
  • 100% of stage 2 users reduced their systolic blood pressure. The mean result was a 25.3 mmHg improvement in 30 days
  • 86% of stage 2 users reduced their risk category (i.e., moved to hypertension stage 1 of 140 to 160, or below)
  • 66% of stage 1 users reduced their systolic blood pressure. The mean result was a 17.7 mmHg improvement in 30 days
  • 56% of stage 1 users reduced their risk category (i.e., moved to prehypertension systolic of 120 to 139, or below)
  • Against a hypothesis of greater than 5 mmHg decrease in systolic, users in both stages showed high statistical significance with p-values below .001
  • Users in both stages sustained lower levels, suggesting persisted adherence, for at least an additional 40 days, after which time insufficient data were available
  • 23% of prehypertension and 9 percent of stage 1 users reduced their systolic blood pressure into the normal range below 120 mmHg

These study results are consistent with Medisafe’s previously announced findings that its users are 86% adherent to their medication regimens, versus the WHO’s estimate of 50 percent for the nation as a whole. Medisafe’s mission is to continue developing the app to better fit the needs of hypertensive patients for improved clinical outcomes – and to tackle the huge issue of high blood pressure in the U.S.

You may also like


New Analysis Shows Reduction in Annual Patient Costs and Medical Claims with Medisafe

BOSTON – Medisafe, a leading digital health company specializing in medication engagement, released the results of a new retrospective, pre- 

..Read More

Download: Navigating Digital Health Amid Economic Uncertainties

Get the latest insights from industry leaders on how digital technologies and health care delivery can withstand changes in the 

..Read More

Download: Digital Patient Engagement Data

Get the latest insights from industry leaders on how pharma can capture greater value from digital patient programs. Download the 

..Read More

Want to Learn More?

We bring decades of experience to your challenges—and technology and solutions uniquely designed to meet your needs.